Vernolide-A inhibits radiation-induced hypoxia-mediated tumor angiogenesis by regulating HIF-1α, MMP-2, MMP-9, and VEGF

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 30, Issue 2, 2011, Pages 139-151

  Pratheeshkumar, P ^a   Kuttan, Girija ^a  

^a AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

Angiogenesis; HIF 1 ; MMPs; Radiotherapy; Tumor hypoxia; VEGF

Indexed keywords

AGAR; COLLAGEN; GELATIN; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SESQUITERPENE LACTONE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VERNOLIDE A;

AGAR DIFFUSION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL INVASION; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION INDUCED NEOPLASM; TUMOR GROWTH; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; ZYMOGRAPHY;

MUS;

EID: 79960032632     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v30.i2.50     Document Type: Article

References (37)

1. Shannon A, Bouchier-Hayes D, Condron C, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003;29:297-307.
2. Escuin D, Simons J, Giannakakou P. Exploitation of the HIF axis for cancer therapy. Cancer Biol Ther. 2004;3:608.
3. Basset P, Okada A, Chenard M, Kannan R, Stoll I, Anglard P, Bellocq J, Rio M. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol. 1997;15:535-41.
4. Rao J. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003;3:489-501.
5. Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005;1755:37-69.
6. Stetler-Stevenson W, Krutzsch H, Wacher M, Margulies I, Liotta L. The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem. 1989;264:1353.
7. Mignatti P, Robbins E, Rifkin D. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 1986;47:487-98.
8. Kaliski A, Maggiorella L, Cengel K, Mathe D, Rouffiac V, Opolon P, Lassau N, Bourhis J, Deutsch E. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther. 2005;4:1717.
9. Karar J, Maity A. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther. 2009;8(21):1994-2001.
10. Nagle D, Zhou Y. Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr drug targets. 2006;7:355.
11. Zhang S, Won Y, Ong C, Shen H. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents. 2005;5:239-49.
12. Kuo Y, Kuo Y, Yu A, Wu M, Ong C, Yang Kuo L, Huang J, Chen C, Li S. Two novel sesquiterpene lactones, cytotoxic vernolide-A and-B, from Vernonia cinerea. Chem Pharm Bull. 2003;51:425-6.
13. Kumar P. P, Kuttan G. Vernonia cinerea L. scavenges free radicals and regulates nitric oxide and proinflammatory cytokines profile in carrageenan induced paw edema model. Immunopharmacol immunotoxicol. 2009;31:94-102.
14. Pratheeshkumar P, Kuttan G. Vernonia cinerea L inhibits tumour cell invasion and pulmonary metastasis in C57BL/6 mice. Integr Cancer Ther. In press.
15. Chea A, Hout S, Long C, Marcourt L, Faure R, Azas N, Elias R. Antimalarial activity of sesquiterpene lactones from Vernonia cinerea. Chem Pharm Bull. 2006;54:1437-9.
16. Jaffe E, Nachman R, Becker C, Minick C. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745.
17. Chen X, Zhan Z, Yue J. Sesquiterpenoids from Vernonia cinerea. Nat Prod Res. 2006;20:31-5.
18. Albini A, Iwamoto Y, Kleinman H, Martin G, Aaronson S, Kozlowski J, McEwan R. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987;47:3239.
19. Billings P, Habres J, Liao D, Tuttle S. Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor. Cancer Res. 1991;51:5539.
20. Postovit L, Adams M, Lash G, Heaton J, Graham C. Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. Int J Cancer. 2004;108:47-53.
21. Diaz-Gonzalez J, Russell J. Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther. 2005;4:1055-62.
22. Hall EJ. The oxygen effect and reoxygenation. In: Hall EJ, ed. Radiobiology for the radiologist. Baltimore: Lippincott Williams & Wilkins; 1994. p. 133-52.
23. Gray L, Conger A, Ebert M, Hornsey S, Scott O. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638.
24. Bergers G, Benjamin L. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-10.
25. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, Harris AL. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85:881-90.
26. Sivridis E, Giatromanolaki A, Gatter K, Harris A, Koukourakis M. Tumor and Angiogenesis Research Group. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer. 2002;95:1055-63.
27. Palayoor S, Mitchell J, Cerna D, DeGraff W, John Aryankalayil M, Coleman C. PX 478, an inhibitor of hypoxia inducible factor 1, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer. 2008;123:2430-7.
28. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581.
29. Liu Y, Poon R, Li Q, Kok T, Lau C, Fan S. Both antiangiogenesis-and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2005;65:3691.
30. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 1996;23:455-64.
31. Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K, Akiba J, Hicklin D, Kojiro M. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. 2000;7(4):725-9.
32. Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-76.
33. Zocchi M, Ferrero E, Leone B, Rovere P, Bianchi E, Toninelli E, Pardi R. CD31/PECAM 1 driven chemokine independent transmigration of human T lymphocytes. Eur J Immunol. 1996;26:759-67.
34. Matrisian L. The matrix-degrading metalloproteinases. Bioessays. 1992;14:455-63.
35. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-74.
36. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells. Cancer Res. 2003;63(17):5224-9.
37. Speake W, Dean R, Kumar A, Morris T, Scholefield J, Watson S. Radiation-induced MMP expression from rectal cancer is short lived but contributes to in vitro invasion. Eur J Surg Oncol. 2005;31:869-74.